Give us your best pitch

See allHide authors and affiliations

Science  12 Jun 2015:
Vol. 348, Issue 6240, pp. 1194-1195
DOI: 10.1126/science.348.6240.1194

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


The world of venture capital is a mysterious place to most researchers, as it has its own jargon and customs. Two venture capitalists who work at companies that fund life science startups explain how they got into the business of helping scientific entrepreneurs, what they look for, where they find ideas, and common misconceptions they run into from would-be makers of drugs and diagnostics. Robert Nelsen of ARCH Venture Partners in Seattle, Washington, and Anthony Sun of Aisling Capital in New York City frankly discuss both the ups and downs of this most risky business, which holds the promise of yielding great rewards both for investors and people in need of new options to improve their health.